Walleye Capital LLC Increases Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Walleye Capital LLC increased its shareholding in Dianthus Therapeutics, Inc. by 29.0% during Q1, now holding 106,931 shares valued at approximately $1.94 million.
• Several hedge funds, including Braidwell LP and Vestal Point Capital LP, have also significantly raised their stakes in Dianthus, with 47.53% of shares now owned by institutional investors.
• Wall Street analysts show a positive outlook for Dianthus, with a consensus target price of $54.00 and seven analysts giving a Buy rating on the stock.

Walleye Capital LLC boosted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 29.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,931 shares of the company's stock after purchasing an additional 24,041 shares during the period. Walleye Capital LLC owned about 0.33% of Dianthus Therapeutics worth $1,940,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Octagon Capital Advisors LP increased its holdings in Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares during the period. Braidwell LP boosted its position in Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after acquiring an additional 712,902 shares in the last quarter. Janus Henderson Group PLC boosted its position in Dianthus Therapeutics by 14.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock valued at $23,607,000 after acquiring an additional 136,314 shares in the last quarter. Vestal Point Capital LP boosted its position in Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares in the last quarter. Finally, Woodline Partners LP boosted its position in Dianthus Therapeutics by 20.0% during the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company's stock valued at $6,551,000 after acquiring an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analyst Ratings Changes

DNTH has been the topic of several research reports. William Blair initiated coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Wedbush lifted their price objective on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research report on Thursday, August 21st. Robert W. Baird cut their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $54.00.

Dianthus Therapeutics Price Performance

NASDAQ DNTH traded up $0.56 during mid-day trading on Wednesday, reaching $24.41. The stock had a trading volume of 67,662 shares, compared to its average volume of 322,792. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $32.27. The stock has a market cap of $785.79 million, a PE ratio of -7.53 and a beta of 1.46. The company has a fifty day moving average price of $20.85 and a 200 day moving average price of $20.03.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.